Table of Contents

1 Report Business Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Omics Based Clinical Trials Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Interventional Studies
  • 1.2.3 Observational Studies
  • 1.2.4 Expanded Access Studies
• 1.3 Market by Application
  • 1.3.1 Global Omics Based Clinical Trials Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
  • 1.3.2 Oncology
  • 1.3.3 Cardiology
  • 1.3.4 Respiratory Diseases
  • 1.3.5 Skin Diseases
  • 1.3.6 CNS Diseases
  • 1.3.7 Immunology
  • 1.3.8 Genetic Diseases
  • 1.3.9 Other Indications
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Omics Based Clinical Trials Market Perspective (2017-2028)
• 2.2 Omics Based Clinical Trials Growth Trends by Region
  • 2.2.1 Omics Based Clinical Trials Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Omics Based Clinical Trials Historic Market Size by Region (2017-2022)
  • 2.2.3 Omics Based Clinical Trials Forecasted Market Size by Region (2023-2028)
• 2.3 Omics Based Clinical Trials Market Dynamics
  • 2.3.1 Omics Based Clinical Trials Industry Trends
  • 2.3.2 Omics Based Clinical Trials Market Drivers
  • 2.3.3 Omics Based Clinical Trials Market Challenges
  • 2.3.4 Omics Based Clinical Trials Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Omics Based Clinical Trials Players by Revenue
  • 3.1.1 Global Top Omics Based Clinical Trials Players by Revenue (2017-2022)
  • 3.1.2 Global Omics Based Clinical Trials Revenue Market Share by Players (2017-2022)
• 3.2 Global Omics Based Clinical Trials Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Players Covered: Ranking by Omics Based Clinical Trials Revenue
• 3.4 Global Omics Based Clinical Trials Market Concentration Ratio
  • 3.4.1 Global Omics Based Clinical Trials Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Omics Based Clinical Trials Revenue in 2021
• 3.5 Omics Based Clinical Trials Key Players Head office and Area Served
• 3.6 Key Players Omics Based Clinical Trials Product Solution and Service
• 3.7 Date of Enter into Omics Based Clinical Trials Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Omics Based Clinical Trials Breakdown Data by Type

• 4.1 Global Omics Based Clinical Trials Historic Market Size by Type (2017-2022)
• 4.2 Global Omics Based Clinical Trials Forecasted Market Size by Type (2023-2028)

5 Omics Based Clinical Trials Breakdown Data by Application

• 5.1 Global Omics Based Clinical Trials Historic Market Size by Application (2017-2022)
• 5.2 Global Omics Based Clinical Trials Forecasted Market Size by Application (2023-2028)

6 North America

• 6.1 North America Omics Based Clinical Trials Market Size (2017-2028)
• 6.2 North America Omics Based Clinical Trials Market Size by Type
  • 6.2.1 North America Omics Based Clinical Trials Market Size by Type (2017-2022)
  • 6.2.2 North America Omics Based Clinical Trials Market Size by Type (2023-2028)
  • 6.2.3 North America Omics Based Clinical Trials Market Share by Type (2017-2028)
• 6.3 North America Omics Based Clinical Trials Market Size by Application
  • 6.3.1 North America Omics Based Clinical Trials Market Size by Application (2017-2022)
  • 6.3.2 North America Omics Based Clinical Trials Market Size by Application (2023-2028)
  • 6.3.3 North America Omics Based Clinical Trials Market Share by Application (2017-2028)
• 6.4 North America Omics Based Clinical Trials Market Size by Country
  • 6.4.1 North America Omics Based Clinical Trials Market Size by Country (2017-2022)
  • 6.4.2 North America Omics Based Clinical Trials Market Size by Country (2023-2028)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Omics Based Clinical Trials Market Size (2017-2028)
• 7.2 Europe Omics Based Clinical Trials Market Size by Type
  • 7.2.1 Europe Omics Based Clinical Trials Market Size by Type (2017-2022)
  • 7.2.2 Europe Omics Based Clinical Trials Market Size by Type (2023-2028)
  • 7.2.3 Europe Omics Based Clinical Trials Market Share by Type (2017-2028)
• 7.3 Europe Omics Based Clinical Trials Market Size by Application
  • 7.3.1 Europe Omics Based Clinical Trials Market Size by Application (2017-2022)
  • 7.3.2 Europe Omics Based Clinical Trials Market Size by Application (2023-2028)
  • 7.3.3 Europe Omics Based Clinical Trials Market Share by Application (2017-2028)
• 7.4 Europe Omics Based Clinical Trials Market Size by Country
  • 7.4.1 Europe Omics Based Clinical Trials Market Size by Country (2017-2022)
  • 7.4.2 Europe Omics Based Clinical Trials Market Size by Country (2023-2028)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic Countries

8 Asia-Pacific

• 8.1 Asia-Pacific Omics Based Clinical Trials Market Size (2017-2028)
• 8.2 Asia-Pacific Omics Based Clinical Trials Market Size by Type
  • 8.2.1 Asia-Pacific Omics Based Clinical Trials Market Size by Type (2017-2022)
  • 8.2.2 Asia-Pacific Omics Based Clinical Trials Market Size by Type (2023-2028)
  • 8.2.3 Asia-Pacific Omics Based Clinical Trials Market Share by Type (2017-2028)
• 8.3 Asia-Pacific Omics Based Clinical Trials Market Size by Application
  • 8.3.1 Asia-Pacific Omics Based Clinical Trials Market Size by Application (2017-2022)
  • 8.3.2 Asia-Pacific Omics Based Clinical Trials Market Size by Application (2023-2028)
  • 8.3.3 Asia-Pacific Omics Based Clinical Trials Market Share by Application (2017-2028)
• 8.4 Asia-Pacific Omics Based Clinical Trials Market Size by Region
  • 8.4.1 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2017-2022)
  • 8.4.2 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2023-2028)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Omics Based Clinical Trials Market Size (2017-2028)
• 9.2 Latin America Omics Based Clinical Trials Market Size by Type
  • 9.2.1 Latin America Omics Based Clinical Trials Market Size by Type (2017-2022)
  • 9.2.2 Latin America Omics Based Clinical Trials Market Size by Type (2023-2028)
  • 9.2.3 Latin America Omics Based Clinical Trials Market Share by Type (2017-2028)
• 9.3 Latin America Omics Based Clinical Trials Market Size by Application
  • 9.3.1 Latin America Omics Based Clinical Trials Market Size by Application (2017-2022)
  • 9.3.2 Latin America Omics Based Clinical Trials Market Size by Application (2023-2028)
  • 9.3.3 Latin America Omics Based Clinical Trials Market Share by Application (2017-2028)
• 9.4 Latin America Omics Based Clinical Trials Market Size by Country
  • 9.4.1 Latin America Omics Based Clinical Trials Market Size by Country (2017-2022)
  • 9.4.2 Latin America Omics Based Clinical Trials Market Size by Country (2023-2028)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Omics Based Clinical Trials Market Size (2017-2028)
• 10.2 Middle East & Africa Omics Based Clinical Trials Market Size by Type
  • 10.2.1 Middle East & Africa Omics Based Clinical Trials Market Size by Type (2017-2022)
  • 10.2.2 Middle East & Africa Omics Based Clinical Trials Market Size by Type (2023-2028)
  • 10.2.3 Middle East & Africa Omics Based Clinical Trials Market Share by Type (2017-2028)
• 10.3 Middle East & Africa Omics Based Clinical Trials Market Size by Application
  • 10.3.1 Middle East & Africa Omics Based Clinical Trials Market Size by Application (2017-2022)
  • 10.3.2 Middle East & Africa Omics Based Clinical Trials Market Size by Application (2023-2028)
  • 10.3.3 Middle East & Africa Omics Based Clinical Trials Market Share by Application (2017-2028)
• 10.4 Middle East & Africa Omics Based Clinical Trials Market Size by Country
  • 10.4.1 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2017-2022)
  • 10.4.2 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2023-2028)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Parexel International Corporation
  • 11.1.1 Parexel International Corporation Company Details
  • 11.1.2 Parexel International Corporation Business Overview
  • 11.1.3 Parexel International Corporation Omics Based Clinical Trials Introduction
  • 11.1.4 Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.1.5 Parexel International Corporation Recent Developments
• 11.2 Pharmaceutical Product Development (PPD)
  • 11.2.1 Pharmaceutical Product Development (PPD) Company Details
  • 11.2.2 Pharmaceutical Product Development (PPD) Business Overview
  • 11.2.3 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Introduction
  • 11.2.4 Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.2.5 Pharmaceutical Product Development (PPD) Recent Developments
• 11.3 Charles River Laboratory
  • 11.3.1 Charles River Laboratory Company Details
  • 11.3.2 Charles River Laboratory Business Overview
  • 11.3.3 Charles River Laboratory Omics Based Clinical Trials Introduction
  • 11.3.4 Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.3.5 Charles River Laboratory Recent Developments
• 11.4 ICON plc
  • 11.4.1 ICON plc Company Details
  • 11.4.2 ICON plc Business Overview
  • 11.4.3 ICON plc Omics Based Clinical Trials Introduction
  • 11.4.4 ICON plc Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.4.5 ICON plc Recent Developments
• 11.5 SGS SA
  • 11.5.1 SGS SA Company Details
  • 11.5.2 SGS SA Business Overview
  • 11.5.3 SGS SA Omics Based Clinical Trials Introduction
  • 11.5.4 SGS SA Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.5.5 SGS SA Recent Developments
• 11.6 Eli Lilly and Company
  • 11.6.1 Eli Lilly and Company Company Details
  • 11.6.2 Eli Lilly and Company Business Overview
  • 11.6.3 Eli Lilly and Company Omics Based Clinical Trials Introduction
  • 11.6.4 Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.6.5 Eli Lilly and Company Recent Developments
• 11.7 Pfizer
  • 11.7.1 Pfizer Company Details
  • 11.7.2 Pfizer Business Overview
  • 11.7.3 Pfizer Omics Based Clinical Trials Introduction
  • 11.7.4 Pfizer Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.7.5 Pfizer Recent Developments
• 11.8 Covance
  • 11.8.1 Covance Company Details
  • 11.8.2 Covance Business Overview
  • 11.8.3 Covance Omics Based Clinical Trials Introduction
  • 11.8.4 Covance Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.8.5 Covance Recent Developments
• 11.9 Rebus Bio
  • 11.9.1 Rebus Bio Company Details
  • 11.9.2 Rebus Bio Business Overview
  • 11.9.3 Rebus Bio Omics Based Clinical Trials Introduction
  • 11.9.4 Rebus Bio Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.9.5 Rebus Bio Recent Developments
• 11.10 Novo Nordisk
  • 11.10.1 Novo Nordisk Company Details
  • 11.10.2 Novo Nordisk Business Overview
  • 11.10.3 Novo Nordisk Omics Based Clinical Trials Introduction
  • 11.10.4 Novo Nordisk Revenue in Omics Based Clinical Trials Business (2017-2022)
  • 11.10.5 Novo Nordisk Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details

Summary:

Market Analysis and Insights: Global Omics Based Clinical Trials Market
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
The global Omics Based Clinical Trials market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Interventional Studies accounting for % of the Omics Based Clinical Trials global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Oncology segment is altered to an % CAGR throughout this forecast period.
China Omics Based Clinical Trials market size is valued at US$ million in 2021, while the North America and Europe Omics Based Clinical Trials are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Omics Based Clinical Trials landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Omics Based Clinical Trials market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Omics Based Clinical Trials market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Omics Based Clinical Trials market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Omics Based Clinical Trials market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the Omics Based Clinical Trials market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
Omics Based Clinical Trials Breakdown Data by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Omics Based Clinical Trials Breakdown Data by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
Frequently Asked Questions
What factors will challenge the Omics Based Clinical Trials market growth?
Which end-use segment will expand at the fastest CAGR in the Omics Based Clinical Trials market?
Which are the emerging players in the Omics Based Clinical Trials market?
How concentrated is the Omics Based Clinical Trials market?
Which factors are positively contributing to the Omics Based Clinical Trials market growth?
Which are the novel product innovations in the Omics Based Clinical Trials market?
Which product segment will emerge as the most lucrative in the Omics Based Clinical Trials market?
Which factors are increasing the competition in the Omics Based Clinical Trials market?
Which are the strategic measures taken by the Omics Based Clinical Trials industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Omics Based Clinical Trials market in the coming years?